Bone mineral density in patients with metastatic prostate cancer with or without androgen deprivation therapy
APMC-Annals of Punjab Medical College. 2011; 5 (1): 7-14
Dans Anglais
| IMEMR
| ID: emr-175237
ABSTRACT
Prostate cancer commonly metastatize to skeletal sites. Androgen deprivation therapy [ADT], the primary treatment of metastatic prostate cancer, may result in osteoporosis. Bone mineral density evaluation during androgen deprivation therapy can detect patients at risk of osteoporotic fractures
Recherche sur Google
Indice:
Méditerranée orientale
langue:
Anglais
Texte intégral:
Ann. Punjab Med. Coll.
Année:
2011
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS